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Abstract: Lapatinib is a dual tyrosine kinase inhibitor of epidermal growth factor receptor 
(EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER2/ErbB2). EGFR and HER2 
overexpression is associated with aggressive breast cancer with a high risk of disease relapse 
and death. Although lapatinib targets both EGFR and HER2, its effects on HER2 appear to be 
more critical. The role of lapatinib in the first-line setting remains unclear. A phase II first-line 
monotherapy lapatinib trial in HER2-therapy-naïve metastatic breast cancer (MBC) patients 
confirms efficacy in HER2-positive tumors. Retrospective analysis of a phase III, first-line 
MBC study confirmed incremental benefit from lapatinib and paclitaxel over paclitaxel alone 
in HER2-positive disease. A prospective phase III study confirms superiority of letrozole and 
lapatinib over letrozole alone in HER2-positive MBC. Further investigation is required to define 
the potential first-line role for lapatinib. Particular strengths appear to be its manageable toxicity 
profile, lack of cross resistance with trastuzumab, activity in central nervous system disease, 
and synergy in combination with other anticancer therapy. Current limitations are lack of dosing 
recommendations from early trials, lack of predictive biomarkers beyond HER2 status, and 
lack of large prospective phase III trials for HER2-positive disease in the first-line setting. The 
role of lapatinib in HER2-negative disease is unclear.
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Introduction
Metastatic breast cancer (MBC) is the leading cause of cancer death for women 
worldwide. Women with breast cancer that overexpresses the human epidermal growth 
factor receptor 2 (HER2) have increased likelihood of disease relapse and death from 
breast cancer.
Traditionally, cancer treatments have been trialed without identification of a specific 
molecular target or biomarker for prediction of response. Cytotoxic chemotherapy has 
focused on DNA damage and disruption of the cell cycle in rapidly dividing cells, with 
nonselective cell death and considerable toxicity from healthy tissue damage. Some 
patients experience these adverse effects for no or limited benefit. Recognition of 
breast cancer as a biologically heterogeneous disease and increased understanding of 
the molecular complexities underlying breast cancer development and progression have 
led to development and implementation of rationally designed targeted-therapeutics.
Potential therapeutic targets are the signaling pathways recruited by the tumor 
for survival and progression. It is not only the presence of drug target, but also 
the functional implications of blocking the target that are important. The ErbB 
receptors are appealing treatment targets due to their pivotal role in breast cancer. Cancer Management and Research 2010:2 14
Oakman et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
ErbB1 overexpression occurs in 20% to 30% of all primary 
breast cancer. ErbB2, perhaps the most studied member of 
the type I receptor tyrosine kinase family, is overexpressed 
in approximately 20% of breast cancer. Despite epider-
mal growth factor receptor (EGFR) overexpression and 
its association with worse prognosis, targeting the EGFR 
receptor has not shown meaningful activity in breast cancer. 
In contrast, therapies targeting the HER2 receptor and 
HER2 tyrosine kinase have shown great clinical efficacy in 
this tumor subtype with a poor natural history. Anti-HER2 
treatments have clinical activity as monotherapy and in 
combination with cytotoxic agents, other targeted agents 
and endocrine agents. This review focuses on lapatinib, 
the small molecule tyrosine kinase inhibitor of both EGFR 
and HER2. The role of lapatinib in the first-line treatment 
of patients with metastatic breast cancer is, with current 
evidence, undefined. Review of lapatinib pharmacology, effi-
cacy and tolerability and an overview of available lapatinib 
data allow us to identify lapatinib strengths and challenges, 
and propose its potential role in the first-line therapy of 
metastatic breast cancer.
ErbB receptors
The type I receptor tyrosine kinase family (ErbB) consists of 
4 transmembrane receptors: ErbB1 (EGFR), ErbB2 (HER2), 
ErbB3 and ErbB4. ErbB2 has no exogenous ligand. ErbB3 
has no kinase activity. Ligand binding of these ErbB receptors 
causes formation of heterodimers or homodimers, in turn 
inducing autophosphorylation of specific tyrosine kinase 
residues within conserved catalytic domains of the ErbB 
receptors. Tyrosine kinase autophosphorylation establishes 
binding sites for Src-homology 2 and phosphotyrosine 
binding domain containing proteins, linking ErbB to activa-
tion of downstream intracellular pathways of cell proliferation 
(mitogen-activated protein kinase (MAPK) pathway) and cell 
survival (the phosphotidylinositol-3-kinase (PI3K) pathway). 
ErbB2, whilst having no exogenous ligand, is the preferred 
partner for heterodimerization with ErbB1, ErbB3 and ErbB4 
as it amplifies the mitogenic signal with potent growth and 
survival effects.
It is the key role of ErbB receptors in tumor cell growth 
and survival that make them such attractive therapeutic targets. 
Monoclonal antibodies, such as cetuximab and trastuzumab, 
target the extracellular domains of ErbB1 and ErbB2 receptors 
respectively. Small-molecule intracellular tyrosine kinase 
inhibitors of ErbB1 include erlotinib, gefitinib, and lapatinib, 
which also inhibits the HER2 tyrosine kinase. Targeting the 
EGFR receptor in breast cancer has not shown meaningful 
clinical activity. Conversely the efficacy of agents targeting 
the HER2 receptor has provided a marked improvement in 
the outlook for patients with HER2-positive disease.
Lapatinib
Lapatinib (GW572016) (Tykerb®/Tyverb®; GlaxoSmithKline) 
is an orally active, small molecule which reversibly inhibits 
both ErbB1 and ErbB2 (Figure 1). This concurrent inhibition 
in ErbB1-expressing and ErbB2-overexpressing tumors 
blocks the activating signaling cascades in the MAPK and 
PI3K pathways resulting in growth arrest and/or apoptosis, 
as shown in cell line and xenograft models.1,2 Preclinical 
models show this may be cytostatic or cytotoxic depending 
on cell type.
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The potential efficacy of lapatinib depends on the inherent 
biological profile of a tumor. A tumor with dependence on 
the EGFR and/or HER2 for cell proliferation and survival is 
the ideal target for lapatinib. Tumors with innate or evolved 
survival mechanisms which are not EGFR and/or HER2 
dependent will show resistance or reduced sensitivity to 
therapy. Although lapatinib targets both EGFR and HER2, its 
effects on HER2 appear to be more critical to its efficacy.
Pharmacology and pharmacokinetics
Lapatinib was developed as an oral agent and has no intrave-
nous equivalent. It is available as a 250 mg tablet and currently 
recommended as a single dose at least 1 hour before or after a 
meal.3 After an oral dose, measurable lapatinib concentrations 
appear in the serum after 15 to 30 minutes. Pharmacokinetic 
(PK) studies reveal peak serum lapatinib concentrations 
3 to 6 hours after dosing.4–7 Serum concentrations increase 
with increased dose, although variability is high. Lapatinib 
displays a time dependent increase in systemic exposure 
with repeated dosing, with serum concentrations accumulat-
ing approximately 2-fold with daily administration. Thus PK 
after the initial dose is not reflective of chronic levels. Steady 
state is achieved within 6 to 7 days suggesting a half-life of 
approximately 24 hours.
Lapatinib is highly bound to albumin (99%) and alpha-1 
acid glycoprotein. The volume of distribution of the terminal 
phase of lapatinib is 2200 L, indicating good drug distri-
bution. Serum concentrations of lapatinib are limited by low 
solubility, low permeability and extensive first pass metabolism 
by cytochrome P-450 enzymes CYP3A4 and CYP3A5, and 
to a lesser extent by CYP2C19 and CYP2C8.7 One metabolite 
(GW690006) remains active against EGFR but not HER2.8 
Less than 2% of lapatinib is excreted in the urine.
PK variations may be attributable to concurrent medica-
tions that inhibit or induce CYP3A4 or CYP3A5. Strong 
CYP3A4/5 inhibitors, for example azoles, antifungals, clar-
ithromycin and grapefruit, should be avoided. If coadminis-
tration is essential, reduction in the lapatinib dose to 500 mg 
once daily may appropriately compensate.3 Conversely, 
strong CYP3A4 inducers, eg, phenytoin, carbamazepine, 
dexamethasone, St. John’s Wort, will reduce lapatinib serum 
levels and dose elevation may be required to maintain serum 
levels. Coadministration of lapatinib with other anticancer 
agents did not meaningfully alter pharmacokinetics compared 
with those for either agent alone.9–11
Renal impairment does not require dose alterations. 
Hepatic metabolism requires that severe hepatic impairment 
be matched by dose reduction, predicted as a reduction from 
1250 mg once daily to 750 mg once daily to adjust the AUC 
to the normal range. However there are no clinical data test-
ing this dose adjustment.3
Lapatinib dosing
There is uncertainty about the optimal dose and schedule 
of lapatinib.12 In a phase I assessment of healthy volunteers, 
the highest administered dose was 175 mg once daily.4 In the 
first phase I trial to assess lapatinib dose escalation in heavily 
pre-treated cancer patients (n = 64), the highest administered 
dose was 1800 mg once daily and the minimum dose with 
clinical activity was 650 mg once daily. Phase I trials report 
responses for lapatinib monotherapy at doses ranging from 
650 to 1800 mg, generally 900 to 1200 mg daily.5,7 Lapatinib 
monotherapy at 500 mg twice daily in a fasting state has 
been reported to have equal efficacy and toxicity to 1500 mg 
once daily.13
A challenge, not only with lapatinib but also with other 
novel targeted therapies, is the paradigm shift away from 
maximum tolerated dose (MTD) to minimum effective dose. 
Targeted therapies, by their very nature of being ‘targeted’, 
are not associated with the systemic, dose limiting toxicities 
seen with traditional cytotoxic chemotherapy agents. As such, 
maximum administered doses in early trials may well exceed 
the dose required for efficacy. Although maximum tolerated 
or administered dose may be reported, the clinical utility of 
such information may be low. Incorporation of alternative 
endpoints for targeted agents in phase I trial design, such as 
pharmacokinetic and pharmacodynamic parameters, may be 
more useful for optimal application of results. Such endpoints 
may include plasma drug levels, measurement of surrogate 
markers for biological activity, or identification of drug target 
and subsequent target inhibiting dose.
Lapatinib and food
Oral administration is convenient, however attention must 
be given to potential sources of variability in drug exposure, 
particularly the effect of dosing with food which increases 
the bioavailability of lapatinib. In a phase I, open label trial 
(n = 27), serum drug levels were measured on 3 occasions, 
1 week apart.14 For each patient, a single 1500 mg oral dose 
of lapatinib was administered after a standardized high fat 
meal, a standardized low fat meal and in the fasting state. 
The conditions were strict: the fasting state was dosing in 
the morning after an overnight fast with maintenance of 
the fast for 4 hours post dose; immediate dosing follow-
ing a prespecified low fat breakfast (2 g fat, 520 calories); 
immediately following a prespecified high fat breakfast Cancer Management and Research 2010:2 16
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(54 g, 1036 calories). In comparison to the fasting state, the 
low fat breakfast was related to 2.67-fold increase in AUC 
and 2.42-fold increase in maximum concentration (Cmax). 
The high fat breakfast increased AUC by 4.25-fold and Cmax 
by 3.03-fold. Due to the marked variation in bioavailability, 
this study was practical in advising lapatinib dosing in 
the fasted state to achieve consistent therapeutic exposure.
Taking lapatinib with food may decrease the required dose 
and associated expense. However oral intake in patients with 
advanced malignancy is often poor and markedly variable 
due to disease related anorexia, nausea and vomiting, and 
medication side effects, especially opiate induced nausea 
and constipation. Dependence of lapatinib dosing on regular 
oral intake may be hazardous, associated with underdosing 
with reduced efficacy or overdosing with escalated toxicity. 
To advise dosing with food, it would be essential to show 
that food effects were reasonably consistent, with supporting 
pharmacokinetic and pharmacodynamic studies.
Lapatinib and HeR2 status
Clinical evidence supports the use of  lapatinib in HER2-positive 
disease.7,13,15–18 The role of lapatinib in HER2-negative disease 
remains unclear.18 Thus, determination of HER2 status is a 
critical step in optimal prescription of lapatinib. Considerable 
debate exists on which test represents the best assessment of 
HER2. Patients with a false negative result will miss poten-
tially efficacious HER2 targeted treatment. Conversely a 
false positive HER2 result may expose patients to ineffective 
yet potentially toxic anti-HER2 therapy. Detection methods 
include immunohistochemistry (IHC) and fluorescence in 
situ hybridization (FISH). Expert guidelines have been pub-
lished in an attempt to standardize assessment. The American 
Society of Clinical Oncology (ASCO) and the College of 
American Pathologists (CAP) have developed guidelines for 
HER2 analysis.19 The recommendations for a positive HER2 
result are IHC staining of 3+ (uniform, intense membrane 
staining of  30% of invasive tumor cells), a FISH result 
of  6 HER2 gene copies per nucleus or a FISH ratio (HER2 
gene signals to chromosome 17 signals) of 2.2. These 
guidelines have limitations, particularly the presumption of 
homogenous HER2 expression within a tumor. HER2 expres-
sion may vary within a tumor and a patient with focal HER2 
amplification in a predominantly HER2-negative tumor may 
benefit from HER2 targeted therapy despite having HER2-
negative disease using the standardized criteria.
HER2 status discordance between IHC and FISH, 
compounded by discordance between local and central 
laboratories, may influence our interpretation of lapatinib 
trial results. For example in the phase III trial assessing 
capecitabine with lapatinib or placebo, trial enrolment 
required that patients had HER2 positive disease defined by 
IHC 3+ or 2+ with gene amplification by FISH by local institu-
tional laboratory.11 Central analysis of archived primary tumor 
or biopsy of metastatic site was carried out. Of 315 patients 
with adequate tissue for HER2 assessment, central analysis 
confirmed HER2-positive status in only 241 patients (77%).
Another issue regarding HER2 is whether to confirm 
HER2 status at the time of recurrent, metastatic disease. 
Retesting HER2 on archived tissue would allow application of 
current diagnostic criteria. However, a known number of false 
positive IHC 3+ results are obtained when assessing HER2 
status in paraffin-embedded breast cancer tissue. A biopsy 
from a metastatic deposit allows reassessment of disease 
HER2 status. Tumor cell characteristics may have changed 
or clonal progression to metastatic disease may have arisen 
from a minority population in the primary tumor.20 A potential 
alternative to invasive biopsy of metastatic sites is isolation 
and bio-characterization of circulating tumor cells (CTC). 
CTC analysis of HER2 status has revealed shift in HER2 
status between primary tumor and metastatic disease, with 
either loss or gain of HER2 over expression.21,22 Systemic 
application of a focal biopsy result presumes biological 
homogeneity in the metastatic disease, which may also have 
limitations due to biological diversity in metastatic sites.
Clinical efficacy
Evidence for the efficacy of lapatinib in MBC derives from 
Phase I–III trials of monotherapy and concurrent administra-
tion of lapatinib with cytotoxic chemotherapy, other targeted 
treatments or endocrine agents. Most early trials were per-
formed in patients with advanced disease, heavily pretreated 
with chemotherapy with or without trastuzumab. Phase I and 
II studies reveal good tolerance and preliminary single agent 
clinical activity for lapatinib monotherapy despite multiple 
lines of prior chemotherapy and trastuzumab, indicating 
lapatinib activity beyond failure of standard therapies.5–7,15 
In a pivotal phase III study in MBC assessing capecitabine 
with or without lapatinib in trastuzumab pre-treated patients, 
an interim analysis of time to progression (TTP) showing 
superiority of the combination and lack of safety concerns 
led to early reporting.11 Longer median TTP was seen 
for capecitabine and lapatinib versus capecitabine alone 
(8.4 months vs 4.4 months respectively, hazard ratio [HR] 
0.49; 95% confidence interval [CI] 0.34 to 0.71; P  0.001). 
Dual ErbB2 blockade has also been trialled in patients 
progressing on trastuzumab. Simultaneous inhibition of the Cancer Management and Research 2010:2 17
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ErbB2 receptor by trastuzumab, which binds the extracellular 
domain of ErbB2, and lapatinib, which binds the intracellular 
kinase, showed superiority over lapatinib therapy alone.10,23 
In a phase III trial, patients (n = 296) receiving the combina-
tion had significantly improved progression-free survival 
(PFS) (12.0 weeks for the combination vs 8.4 weeks for lapa-
tinib monotherapy; HR 0.77; 95% CI 0.6 to 1.0; P = 0.029) 
and clinical benefit rate (CBR) (25.2 vs 13.2%; P = 0.020).23 
There was no observed difference for overall survival (OS).
In the first-line setting, although evidence is evolving it 
is neither extensive nor conclusive. Three published trials 
of upfront therapy in the metastatic setting include lapatinib 
monotherapy, lapatinib in combination with paclitaxel, and 
lapatinib plus letrozole13,17,18 (see Table 1).
First-line lapatinib monotherapy
Lapatinib monotherapy demonstrated activity as first-line 
therapy in HER-2 overexpressing disease in a phase II trial.13 
Women (n = 138) with HER2-amplified locally advanced or 
MBC were randomized to one of two schedules of lapatinib 
monotherapy: 500 mg twice daily or 1500 mg once daily. 
Background PK data suggested that the 500 mg twice daily 
AUC would be greater and that plasma drug levels would 
vary less with twice daily dosing.24 Equal efficacy for the 
two schedules was reported. Objective response rate (ORR) 
was 24% (1500 mg once daily 22%, 500 mg twice daily 
26%, P = 0.691) – comparable to first-line trastuzumab 
therapy25,26 – and the CBR was 31% (1500 mg once daily 
29%, 500 mg twice daily 33%, P = 0.714). Median time to 
response was 7.9 weeks. Median duration of response was 
28.4 weeks, indicating long term benefit from lapatinib. 
Of note, no patients had received prior trastuzumab and only 
50% had received any adjuvant or neoadjuvant systemic 
therapy. In contrast, most patients now presenting with 
HER2-positive advanced disease will have received adjuvant 
chemotherapy and trastuzumab. The first-line activity of 
lapatinib monotherapy in a more representative population is 
unknown. These results do suggest that in women presenting 
with MBC, with no prior HER2 treatment, lapatinib mono-
therapy may be a reasonable option for first-line treatment.
First-line lapatinib and chemotherapy
As with other targeted agents, combination therapy with 
lapatinib may be the best clinical approach for efficacy and 
duration of response. Paclitaxel is a microtubule damaging 
agent with proven activity in breast cancer. Phase I data 
Table 1 First-line lapatinib trials in metastatic breast cancer
Reference Trial Population Pts Therapy Outcomes
Gomez et al13 Phase ii  
 
Multicenter, randomized, 
open label
HER2-positive 
advanced or MBC
138 Lapatinib 500 mg twice daily 
(n = 69)  
vs  
Lapatinib 1500 mg once daily 
(n = 69)
ORR 24%  
CBR 31%  
PFS 16.1 wk  
Equal efficacy between doses
Di Leo et al17 Phase iii  
 
Multicenter, randomized, 
double-blind, placebo-
controlled
HER2-negative or 
unknown advanced 
or MBC
579 Lapatinib 1500 mg once daily 
plus paclitaxel 175 mg/m2 iv 
every 21 days (n = 291)  
vs  
Placebo plus paclitaxel 
175 mg/m2 iv every 21 days 
(n = 288)
iTT population:  
ORR 35.1% vs 25.3% P = 0.008  
CBR 40.5% vs 31.9% P = 0.025  
eFS 25.1 wk vs 22.6 wk P = 0.238  
 
HER2-positive (n = 86): 
(retrospective analysis)  
ORR 63.3% vs 37.8% P = 0.023  
CBR 69.4% vs 40.5% P = 0.011  
eFS 35.1 wk vs 21.9 wk P = 0.004
Johnston et al18 Phase iii  
 
Multicenter, randomized, 
double-blind, placebo 
control
HR-positive MBC 
in postmenopausal 
women
1286 Lapatinib 1500 mg once daily 
plus letrozole 2.5 mg once daily 
(n = 642) 
vs  
Placebo plus letrozole 2.5 mg 
once daily (n = 644)
iTT population:  
ORR 33% vs 32% P = 0.726  
CBR 58% vs 56% P = 0.761  
PFS 11.9 mo vs 10.8 mo, P = 0.026   
 
HER2-positive pts (n = 219):  
ORR 28% vs 15%, P = 0.021  
CBR 48% vs 29%, P = 0.003  
PFS 8.2 mo vs 3 mo, P = 0.019
Abbreviations: CBR, clinical benefit rate; EFS, event-free survival; HR, hormone receptor; ITT, intent to treat; IV, intravenous; MBC, metastatic breast cancer; MO, months; 
ORR, objective response rate; PFS, progression-free survival; Pts, patients; WK, weeks.Cancer Management and Research 2010:2 18
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from patients with refractory disease (n = 26) supported the 
use of combination paclitaxel and lapatinib, with objective 
responses (OR) in 3 patients with taxane resistant MBC and 
stable disease (SD) 12 weeks in 7 patients.27
A large multicenter, randomized, double-blind phase III 
trial assessed the combination of lapatinib and paclitaxel in the 
first-line metastatic setting.17 A primary goal of this trial was 
to explore the efficacy of lapatinib in women with advanced 
tumors without HER2 amplification/overexpression. Women 
(n = 579) with HER2-negative or HER2-uncharacterized 
MBC were randomized to paclitaxel 175 mg/m2 iv every 
21 days plus lapatinib 1500 mg once daily or placebo. OR 
were reported in 35% and 25.3% of patients in the pacli-
taxel-lapatinib arm and paclitaxel-placebo arm, respectively 
(P = 0.008). However, there was no significant difference in 
TTP or OS between the treatment arms. From a preplanned, 
retrospective, blinded, central analysis of tumor tissue for 
HER2 using FISH and IHC, 86 patients were found to have 
HER2-positive disease. For patients with both FISH and IHC, 
there was, as expected, a strong association between HER2 
gene amplification and HER2 protein overexpression. For 
the HER2-negative patients, no differences were seen for any 
outcome. However, for the HER2-positive minority, treatment 
with lapatinib/paclitaxel resulted in statistically significant 
improvements in TTP, event-free survival (EFS), ORR and 
CBR. No significant OS benefit was reported. These patients 
are small in number and were not randomized by HER2 status, 
but they were well balanced between the treatment groups. 
Median TTP for the paclitaxel/lapatinib-treated HER2-postive 
patients was 36.4 weeks compared with 25.1 weeks in the 
paclitaxel/placebo-treated patients (unadjusted HR of 0.53; 
95% CI 0.31 to 0.89; P = 0.005). In the paclitaxel/lapatinib 
versus the paclitaxel/placebo treated patients, ORR (63.3% 
vs 37.8% respectively, P = 0.023) and CBR (69.4% vs 
40.5%, respectively, P = 0.011) were significantly higher. 
Thus, additional benefit from lapatinib was reported only in 
women with HER2-amplified disease, indicating that lapa-
tinib exerts its primary effects through inhibiting the HER2 
pathway. Despite lapatinib being a dual kinase inhibitor, 
EGFR did not show any correlation with clinical efficacy. 
These preliminary, hypothesis generating results require 
prospective confirmation. A current trial is prospectively 
assessing first-line lapatinib and weekly paclitaxel 80 mg/m2 
in HER2-positive MBC.
First-line lapatinib and endocrine agents
Despite documentation of HER2-positive and hormone 
receptor (HR)-positive status in MBC, many patients will 
display resistance to anti-HER2 therapy and/or endocrine 
therapy. A potential mechanism of resistance is downstream 
crosstalk between ErbB2 and HR signaling pathways. Dual 
blockade of HER2 and HR may overcome this crosstalk and 
improve outcomes. In the endocrine treatment of HR-positive 
HER2-positive tumors, in which overexpression of HER2 
may confer resistance to endocrine therapy, concurrent inhibi-
tion of HR and ErbB2 may enhance efficacy. In addition, in 
HR-positive HER2-negative tumors, the early use of ErbB 
inhibitors may prevent or limit the upregulation of ErbB 
pathways that often occurs in the progression of disease.28 
To this ends, several targeted agents are being investigated 
in combination with endocrine therapy.29–31 Trastuzumab 
plus anastrazole has shown improved PFS over endocrine 
blockade alone in women with HR-positive HER-2 positive 
MBC, and gefitinib plus anastrazole was superior to anas-
trazole alone in HR-positive MBC patients.29,30
A recently reported phase III trial randomized post meno-
pausal women with HR-positive MBC (n = 1286) to the non-
steroidal aromatase inhibitor letrozole 2.5 mg once daily plus 
placebo or lapatinib 1500 mg once daily as first-line therapy.18 
Prior neoadjuvant/adjuvant antiestrogen therapy was allowed, 
as were adjuvant aromatase inhibitors and trastuzumab if 
discontinued 12 months prior to trial entry. In women with 
HR-positive HER2-positive disease (n = 219), after a median 
follow up of 1.8 years, the combination of letrozole-lapatinib 
was superior to letrozole alone, with median PFS of 8.2 and 
3.0 months, respectively (HR = 0.71, 95% CI 0.53 to 0.96, 
P = 0.019). Lapatinib-letrozole also improved CBR (48% vs 
29%). There was no significant improvement in OS, however 
less than 50% of OS events had occurred at time of reporting. 
Patients with HR-positive HER2-negative disease (n = 952) 
had no improvement in PFS. Within this subgroup, patients 
who were endocrine treatment naïve or had not received 
endocrine therapy for 6 months (after a median exposure 
to tamoxifen of 5 years) had no additional benefit from the 
combination over letrozole alone. In contrast, in women 
with 6 months since discontinuation of adjuvant tamoxifen 
therapy, a nonsignificant trend was reported toward pro-
longed PFS (HR = 0.78; 95% CI 0.57 to 1.07; P = 0.117). 
In this group, adjuvant tamoxifen had been administered 
for a median of only 2.8 years, suggesting relative tamoxi-
fen resistance, and median time since discontinuation was 
only 1 month. Thus, within the HER2-negative population, 
targeting the EGFR/HER2 receptor may add benefit and 
may reflect a more prominent role played by growth factor 
signaling. Lack of PR expression has been postulated as a 
surrogate for endocrine resistance. This trial supports the use Cancer Management and Research 2010:2 19
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of combined therapy of letrozole and lapatinib in patients 
with HR-positive HER2-positive disease over letrozole alone. 
Within the HER2-negative HR-positive patients, no clinically 
meaningful results reached statistical significance, however 
further trials assessing biomarkers and stratification based 
on prior responsiveness to endocrine therapy may uncover 
a subgroup with benefit.
Role of lapatinib in CNS metastases
First-line lapatinib, either alone or in combination with 
radiation, surgery or other anticancer treatment, for patients 
with central nervous system (CNS) metastases has not been 
prospectively explored. Observations from the phase II mono-
therapy study were of 6 patients with stable CNS disease at 
study entry, 1 patient had CNS disease as the sole site of dis-
ease progression, 3 patients had systemic progression only, 1 
patient died before documented progression and 1 patient con-
tinued progression free at time of discontinuation.13 Although 
first-line data are currently lacking, CNS activity of lapatinib 
may be a strength in defining its place in therapy.
The CNS remains a concerning site for initial and subse-
quent relapse for patients with HER2-positive breast cancer. 
This may represent an innate tendency of HER2-positive 
tumors to infiltrate the CNS, improved systemic control 
with trastuzumab with longer survival time to develop CNS 
metastases and/or the CNS as a sanctuary site for metastases 
due to poor trastuzumab penetrance across the blood–brain 
barrier (BBB). Monoclonal antibodies are prevented from 
entering the CNS efficiently, predominantly due to their 
large size. In preclinical models, lapatinib did not cross the 
BBB to a significant degree. However in CNS disease, the 
disturbed BBB may have altered permeability, allowing 
passage of lapatinib. In a preclinical model, lapatinib was 
shown to inhibit the formation of brain metastases in a breast 
cancer xenograft mode.32 In this murine model, lapatinib 
inhibited phosphorylation of EGFR, HER2 and associated 
downstream proteins. Of note, lapatinib inhibited formation 
of large metastases but did not completely prevent metastases, 
suggesting resistance in some breast cancer cells.
Lapatinib activity in CNS disease in heavily pre-treated 
patients encourages further research into defining its role in 
the management of CNS metastases. In the phase III trial with 
lapatinib and capecitabine, fewer patients had CNS metasta-
ses in the combination group (n = 4) vs lapatinib monotherapy 
(n = 11), however this was not statistically significant.11 
A phase II analysis of lapatinib in MBC patients (n = 39) with 
new or progressive brain metastases following trastuzumab 
therapy revealed 1 patient with a PR and 7 patients with stable 
CNS and non-CNS disease at 16 weeks.33 Within this trial, an 
exploratory analysis using volumetric assessment rather than 
RECIST for CNS lesions suggested longer TTP in patients 
with 10% volumetric reductions. Whilst this study did not 
reach its primary efficacy goal for response rate based on 
the prospectively defined RECIST criteria, the volumetric 
studies were certainly encouraging. Preliminary data from a 
subsequent trial (n = 104), with volumetric reduction of CNS 
lesions as its primary endpoint, revealed 20% volumetric 
reduction for 17 patients (16.3%) in whom the median time to 
volume progression was 16 weeks (range 12 to 24 weeks).34 
Definitive results are awaited. Furthermore, a trial exten-
sion offered patients with CNS and/or non-CNS progres-
sion on lapatinib alone the option of receiving combination 
lapatinib and capecitabine.35 Preliminary results (n = 40) 
showed 50% reduction in 8 patients (20%) suggesting 
activity of lapatinib-capecitabine beyond lapatinib mono-
therapy resistance.
Lapatinib tolerability
Lapatinib is a generally well tolerated treatment. In phase I 
and II studies, lapatinib monotherapy was associated with 
transient grade 1–2 rash, diarrhea, nausea/vomiting, sto-
matitis, fatigue and anorexia reported as the most frequent 
adverse events (AE).4–7,13,15,16 Grade 3 toxicities were uncom-
mon, but included diarrhea, rash, abnormal liver function and 
gastrointestinal events.5–7 No grade 4 toxicity attributable to 
lapatinib was reported.5–7,13,16 No drug-related cardiac toxicity 
was observed. This seems to be in contrast to the reversible 
cardiomyopathy seen with trastuzumab therapy, although 
no direct comparison data are available. There was no drug-
related interstitial pneumonitis.
Diarrhea
Lapatinib associated diarrhea correlates with dose but not 
with serum concentration.7 This suggests that the diarrhea 
is due to a local effect on the gut epithelium. The issue 
about drug dosing may be pertinent to diarrhea as it is 
dose dependent. Lower doses due to administration with 
food or twice daily scheduling may be associated with less 
diarrhea. A pooled analysis of 9 phase I–III clinical trials 
was undertaken to review diarrhea associated with lapatinib 
as monotherapy or in combination with capecitabine or 
taxanes.36 Lapatinib doses ranged from 1000 to 1500 mg once 
daily. Diarrhea occurred in 55% of lapatinib-treated patients 
and 24% of patients not receiving lapatinib. Overall, most 
diarrhea events were grade 1–2, self-limiting, and manage-
able with conventional approaches. Grade 3 events occurred Cancer Management and Research 2010:2 20
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in 10% of patients and grade 4 events were rare (1%). 
Dose modifications were seldom required. Diarrhea was gen-
erally an early event with onset within 6 days of commencing 
treatment, with a median duration of 7 to 9 days. Although 
the elderly (70 years) patient population was small, the 
incidence of diarrhea events was comparable to that observed 
in younger patients. Proactive management of diarrhea, with 
early implementation of antidiarrhea agents and increased 
fluid, is a crucial component of lapatinib prescription.
Rash
Lapatinib rash is generally mild.7 Interestingly, despite a 
correlation between rash and efficacy for other EGFR inhibi-
tors, no such correlation is seen for lapatinib. Rash has been 
reported to be more prevalent in nonresponders.7 Structurally 
lapatinib, a 4-anilinoquinazoline, differs from erlotinib and 
gefitinib, quinazolines, which may account for the difference 
in rash. In an early study, the rash was independent of serum 
concentration, appeared between 2 and 66 days, generally 
resolved without interruption of treatment and seemed resis-
tant to topical dermatological therapy.7 A pooled analysis of 
dermatological events from lapatinib at doses from 1000 to 
1500 mg once daily in patients (n = 1419) from 9 clinical trials 
of metastatic cancer was also reported.37 Lapatinib was admin-
istered as monotherapy or in combination with capecitabine 
or paclitaxel. Events included hand–foot syndrome, rash, 
hair disorder, dry skin, pruritus/urticaria, skin disorder, skin 
infection, and nail disorder. Lapatinib monotherapy was 
associated with events in 58% of patients: 55% grade 1/2, 3% 
grade 3, no grade 4. The most common event was rash (43%). 
Most events develop early, between days 1 and 14 of starting 
treatment, with a median duration of 29 days. Adverse skin 
events infrequently required lapatinib dose reduction (3%), 
dose interruption (7%) and drug discontinuation (1%).
Cardiotoxicity
Although cardiotoxicity with decreases in left ventricular 
ejection fraction (LVEF) is reported with trastuzumab 
therapy, lapatinib cardiotoxicity is uncommon. In a review 
of cardiac safety in lapatinib treated patients, 1.3% (42 of 
1327) experienced a decrease in LVEF, 23 of whom received 
monotherapy and 19 of whom received it in combination with 
other chemotherapeutic agents.38 Only 4 of the 42 patients 
were symptomatic (0.01%) and they responded to standard 
heart failure treatment. Decreased LVEF occurred within 
9 weeks of treatment initiation in 69% of cases and resolved 
in 62% of patients. 90% had confounding factors: prior 
exposure to adriamycin/cyclophosphamide, radiotherapy 
or trastuzumab. Even in combination with trastuzumab, 
cardiotoxicity is uncommon.10,23
Specific toxicity from first-line 
lapatinib trials
First-line lapatinib monotherapy
In the phase II monotherapy study, AEs considered related 
to lapatinib occurred in 71% of patients.13 The most com-
mon AEs were grade 1–2 diarrhea, rash, pruritis and nausea. 
Grade 3 events were diarrhea (3%), rash (1%) and nausea 
(1%). Serious AEs (SAEs) attributed to lapatinib were 
experienced by 7% of patients. Four patients permanently 
withdrew from the study due to lapatinib related SAEs; 
grade 3 abnormal hepatic function, grade 1 left ventricular 
dysfunction, grade 2 ejection fraction decrease and grade 4 
thrombocytopenia with grade 3 anemia in 1 patient. Six fatal 
AEs were reported, only 1 considered related to lapatinib: a 
73-year-old patient with hepatic failure and bacterial peri-
tonitis, on a background of 223 days of 500 mg oral twice 
daily lapatinib for extensive liver metastases.
First-line lapatinib plus paclitaxel
In keeping with the known side effects of  both drugs, common 
side effects from paclitaxel and lapatinib were diarrhea, 
rash, alopecia, nausea, vomiting, myalgia and neutropenia, 
all generally mild.17 The combination was associated with 
significantly greater toxicity, especially diarrhea and rash. The 
addition of lapatinib resulted in increased grade 3 rash (4% vs 
0%) and grade 3 diarrhea (15% vs 1%). Dose reductions to 
1250 mg once daily in 6% patients and to 1000 mg once daily 
in 1% patients were required for toxicity management. 
AEs resulted in treatment discontinuation in 16% and 7% of 
patients receiving paclitaxel/lapatinib and paclitaxel/placebo 
respectively. Cardiac events were reported in 6 patients in 
each of the treatment groups. In 5 of each group of 6, this 
decrease in LVEF was asymptomatic. There were 8 (2.7%) 
SAE related deaths in the paclitaxel/lapatinib arm and 
2 (0.6%) in the paclitaxel/placebo arm. These fatal AEs in 
the paclitaxel/lapatinib arm were due to septic shock and 
diarrhea (3 patients), septic shock, cerebrovascular accident, 
pulmonary embolism, cardiac arrest and heart failure. The 
cardiac arrest and heart failure were not considered treatment 
related. In the paclitaxel-placebo arm, the deaths were due 
to a cerebrovascular accident and an unknown cause.
First-line lapatinib plus letrozole
Common side effects were diarrhea, rash, nausea, arthralgia 
and fatigue.18 Toxicity was greater in the lapatinib-letrozole Cancer Management and Research 2010:2 21
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arm compared with letrozole-placebo arm, particularly with 
grade 3 or 4 diarrhea (10% vs 1% respectively) and rash 
(1% vs 0% respectively). Of the 60 patients with grade 3 
or 4 diarrhea in the combination arm, 15% required dis-
continuation and 19% required a dose reduction. Cardiac 
toxicity was infrequent with 7 patients having symptomatic 
LVEF decline, 2 from the letrozole/placebo arm and 5 from 
the letrozole/lapatinib arm. Treatment related liver toxicity 
was reported in 1 patient from the letrozole/placebo arm 
and 8 patients from the letrozole-lapatinib arm, 2 of whom 
required drug discontinuation, with subsequent resolution 
of liver function. SAEs occurred in 8% of patients in the 
combination arm and 4% in the letrozole-placebo group. 
There were 8 deaths in each treatment arm. One death from 
hepatobiliary toxicity in the letrozole/lapatinib arm, and 
2 deaths in the letrozole-placebo arm were considered SAE 
related to study drug. Use of the drugs in combination did 
not reveal any new safety concerns for either drug.
Lapatinib resistance
A strength of lapatinib is its noncross resistance with 
trastuzumab. Clinical responses are seen with lapatinib, 
even in HER2-positive MBC patients pretreated with 1 or 
more lines of prior trastuzumab. This lack of cross resistance 
between trastuzumab and lapatinib suggests diverse mecha-
nisms underlying the resistance.
Despite documented HER2 receptor amplification, 
patients may have de novo or acquired resistance to trastu-
zumab.39 Potential mechanisms of trastuzumab resistance 
include altered receptor–antibody interaction (MUC4, 
p95HER2, ErbB2 mutations), altered downstream signaling 
(reduced p27, reduced PTEN, activation of PI3K, activa-
tion of Akt) and crosstalk with other signaling pathways 
(IGF-R1, ER, VEGFR).40 The p95HER2 receptor is created 
either by cleavage and shedding of the extracellular domain 
of the HER2 receptor or by specific mRNA splicing, result-
ing in a constitutively active truncated receptor which is 
associated with a more aggressive phenotype. The intracel-
lular mechanism of action of lapatinib, in contrast to the 
extracellular approach of trastuzumab, results in inhibi-
tion the phosphorylation of p95HER2.41 PTEN reduction or 
deficiency results in increased signaling via the critical 
PI3K/Akt pathway. PTEN loss is associated with a lower 
response to trastuzumab, however lapatinib appears PTEN 
independent and seems to maintain activity despite loss of 
this tumor suppressor.42,43
The efficacy of lapatinib is also limited by resistance.44,45 
This may be mediated by activation of redundant survival 
pathways, rather than ErbB2 receptor mutations. A preclinical 
breast cancer cell model showed outgrowth of cells with 
acquired resistance to lapatinib with prolonged exposure, 
despite initial high sensitivity.45 Resistance was not associated 
with reduced inhibition of the HER2 pathway, but it was asso-
ciated with increased survivin. Prolonged inhibition of ErbB2 
kinase activity resulted in upregulation of the transcription 
factor FOXO3A which upregulates estrogen receptor (ER) 
expression and signaling. Regulation of survivin and tumor 
cell survival switched from ErbB2 alone to ErbB2 and other 
pathways. The lapatinib resistant cells do not entirely aban-
don the HER2 pathway. Instead they develop codependence 
between HER2 and ER pathways.
Quality of life
In the setting of advanced disease, the intention of treatment 
is palliative. An essential component of caring for individuals 
with advanced disease is to improve or maintain quality of 
life (QoL) and to minimize pain. The common QoL issues 
to consider are disease induced pain, immobility, anxiety, 
anorexia and fatigue, and treatment related side effects. 
In combination these effects are potentially profoundly 
disabling in terms of independence, physical activity and 
social functioning.
Lapatinib is an oral treatment so obviates the need 
for intravenous access or oncology day visits for therapy 
administration. Lapatinib is commonly reported as well 
tolerated with mild and manageable side effects. That 
the treatment is well tolerated is indicated by 80% 
compliance.16 About 25% of patients require dose adjust-
ment and/or treatment interruption due to AEs.15 The 
commonest AEs may significantly impair QoL, despite 
being mild or moderate. Depending in the distribution 
and severity of rash, this can impair personal and social 
functioning. Diarrhea can be disabling, even at grade 2 (see 
Table 2). Particularly with the diarrhea, proactive manage-
ment may result in reduced incidence and severity, and 
less impact on QoL.
Published QoL data for lapatinib comes from its 
combination use with capecitabine.46 A QoL analysis was 
undertaken in the study of capecitabine monotherapy versus 
capecitabine and lapatinib using the validated Functional 
Assessment of Cancer Therapy-Breast (FACT-B) and 
EuroQoL (EQ-5D) questionnaires. QoL for patients in 
both treatment groups was maintained, with a suggestion 
of improved QoL for those with combination therapy. In 
an exploratory analysis, mean changes from baseline in all 
QOL scores were similar for both groups. Patients with Cancer Management and Research 2010:2 22
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an OR or SD showed clinically meaningful differences 
in QoL scores compared with patients with progressive 
disease. The challenge of this QoL study however is that 
lapatinib versus placebo was not assessed. The comparison 
was between lapatinib plus capecitabine and capecitabine 
alone, which is itself related to significant disability from 
diarrhea, nausea and rash.
Biomarkers
The use of targeted therapies is likely to be critically guided 
by patient selection and predictive molecular markers. Due 
to biological heterogeneity within MBC, some patients will 
be more likely to benefit from a particular intervention. The 
ideal of individualized anticancer therapy requires predictive 
biomarkers to firstly, identify which patients will benefit, 
and secondly, monitor response. The importance of such 
markers in trial design and in the assessment of efficacy of 
targeted therapies should not be overlooked.
Preclinical and clinical studies support HER2 amplifica-
tion as predictive of response to lapatinib.5–7,15,17,47 In con-
trast, this differential benefit is not evident in patients with 
HER2-negative status, even when HER2 status is centrally 
confirmed.47 Whilst HER2 amplification identifies patients 
who are likely to respond, resistance within this population 
is frequent and HER2 status alone will not be adequate.
EGFR is not predictive of response. This is in contrast to 
EGFR targeting agents in other tumor types, such as EGFR 
status as a predictive biomarker in lung cancer.48 Future 
work may explain the lack of linkage between EGFR over-
expressing triple negative breast cancer and EGFR targeting 
agents. This subgroup of patients currently lacks targeted 
therapeutic options.
Other potential markers include the serum extracellular 
domains (ECD) of EGFR and HER2, and tumor tissue 
analysis of receptor activation by phosphorylation status. 
Baseline levels of serum HER2/ECD are associated with a 
poor prognosis. However neither baseline nor serial measure-
ment of ECD HER2 or ECD EGFR has shown predictive 
capacity.47 High baseline p-ErbB2, low Day 21 p-ErbB2 
and tumor cell apoptosis on Day 21 have been explored 
with promise.
A phase I biomarker substudy, in which patients (n = 33) 
with various tumor types and various lapatinib doses pro-
vided a pre-treatment and a sequential Day 21 biopsy, 
allowed a pilot exploration of the impact of lapatinib on 
growth and survival pathways.49 Four patients with a PR had 
ErbB2 overexpression and high pre-treatment expression of 
phosphorylated (p) ErbB2, which was inhibited by lapatinib. 
Expression of ErbB2 protein was largely unchanged by lapa-
tinib. Clinical response correlated with increased tumor cell 
apoptosis on Day 21. In contrast, both responders and some 
nonresponders displayed varying degrees of inhibition of 
p-ErbB1, pErk1/2, p-Akt and cyclin D1. The nonresponders 
appeared to have lower baseline levels of ErbB2 and p-ErbB2 
than responders. Not all patients with ErbB2 overexpression 
responded. Indeed, ErbB2 overexpression did not always 
correlate with an activated receptor as indicated by low 
levels of p-ErbB2.
In a comparison of baseline tumor blocks and lapatinib 
response in 65 patients, RT-PCR was used to assess ErbB1-4, 
PTEN and c-MYC.50 Elevated ErbB2 was significantly asso-
ciated with lapatinib response (P = 0.02) and longer TTP 
(P  0.0025). Of 17 patients with a response, 16 appeared 
to have a gene expression signature that combined ERBB1, 
ERBB2 and ERBB3. No association was seen for ErbB4, 
PTEN or c-MYC.
A retrospective biomarker substudy from the phase III 
trial of paclitaxel plus lapatinib or placebo explored the 
potential correlation between hormone subtypes and benefit 
from lapatinib.51 For 493 of the 579 patients, IHC determined 
semiquantitative ER, progesterone receptor (PgR) and EGFR, 
and FISH determined HER2 amplification. The subgroups 
were small, but allowed for exploratory analysis between 
biomarker expression and EFS. Interestingly, for the HER2-
positive patients as a group, median EFS was significantly 
improved (8.1 vs 5.0 months; P = 0.008; HR = 0.49; 95% CI 
0.3 to 0.8). However within the HER2-positive subgroup, 
statistically significant lapatinib benefit in EFS was not 
Table 2 National Cancer institute Common Toxicity Criteria 
(NCI-CTC) grading for diarrhea
Toxicity 
grade
Diarrhea 
1 increase of 4 stools/day over baseline  
Mild increase in ostomy output compared with baseline
2 increase of 4–6 stools/day over baseline  
Intravenous fluids 24 h  
Moderate increase in ostomy output compared with 
baseline  
Not interfering with daily living
3 increase of 7 stools/day over baseline  
incontinence  
Intravenous fluids  
Severe increase in ostomy output compared with baseline  
interfering with daily living activities
4 Life-threatening consequences (eg, hemodynamic collapse)
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seen in patients with coexisting ER or PgR positivity. This 
analysis lacked statistical power due to the limited sample 
sizes however even with these patient numbers, heterogeneity 
within the HER2-positive population is evident. The benefit 
seen in the HER2-positive, and ER-negative and PgR-negative 
disease has a strong biological rationale, in that these tumors 
are dependent on ErbB signaling pathways for survival and 
progression. Statistically significant findings were incremen-
tal benefit from the addition of lapatinib in HER2-positive, 
ER-negative and PgR-negative disease (n = 42; 8.3 vs 
5.0 months; P = 0.007) and in HER2-negative, ER-positive 
and PgR-weakly positive disease (n = 50; 7.3 vs 2.4 months; 
P = 0.026). In HER2-negative, ER-positive, PgR-negative 
MBC, lapatinib conferred a worse outcome (n = 40; 3.7 vs 
7.2 months; P = 0.004). No significant benefit was seen in the 
triple negative cancer cohort despite theoretical sensitivity 
due to increased EGFR expression in this subgroup and the 
EGFR inhibition by lapatinib. Although most trial patients 
(71%) were negative for EGFR by IHC (EGFR = 0), the 
majority with a positive result had triple negative disease.
Future and place in therapy 
for lapatinib
The place for lapatinib in the management of MBC will be 
refined with further investigation. Lapatinib is active and well 
tolerated upfront and in patients pretreated with chemother-
apy and trastuzumab. There is biological rationale and clinical 
evidence to support the use of dual EGFR/HER2-targeted 
agents in HER-2 positive disease. The role of lapatinib in 
HER2-negative disease remains unclear. EGFR status has not 
shown correlation with response. In the first-line management 
of MBC, prospective data support concurrent use of lapatinib 
with letrozole in HER2-positive disease. We await results 
of the phase III trial assessing lapatinib and paclitaxel, with 
background retrospective analyses favoring the combination 
therapy in HER2 positive disease.
The optimal duration of lapatinib treatment in MBC is 
unknown. Uncertainty persists regarding choice between 
upfront trastuzumab versus lapatinib, dual versus sequential 
HER2 blockade and best use of lapatinib beyond relapse or 
progression despite anti-HER2 therapy. There are no clear 
answers on whether patients with disease relapse following 
adjuvant trastuzumab are best treated with repeat exposure to 
trastuzumab or a switch to upfront lapatinib. The disease-ree 
interval and tolerance may play a role in deciding rechallenge 
with trastuzumab, additional HER2 blockade with lapatinib 
or lapatinib alone. Similarly for MBC patients progressing on 
lapatinib, there is uncertainty regarding subsequent therapy. 
A reasonable option would be continued blockade of the 
HER2 receptor by lapatinib whilst changing the concurrent 
therapy, however no controlled clinical studies have been 
reported to currently support such an approach.
Biomarkers for prediction of response, measurement of 
response and prediction of toxicity are required. Beyond 
HER2 positive status, refined patient selection is lacking. 
Monitoring, with valuable tools such as CTC may show 
treatment efficacy.52 Although severe toxicity is uncommon, 
clinical tools to predict and thus avoid adverse effects would 
be valuable.
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